龚博锴, 肖岚, 邓珙楠, 张锺权, 贾文锋, 童凡, 高会乐. 肿瘤微环境双响应可变形纳米粒的制备及其用于乳腺癌治疗的研究J. 药学学报, 2025, 60(8): 2615-2625. DOI: 10.16438/j.0513-4870.2025-0703
引用本文: 龚博锴, 肖岚, 邓珙楠, 张锺权, 贾文锋, 童凡, 高会乐. 肿瘤微环境双响应可变形纳米粒的制备及其用于乳腺癌治疗的研究J. 药学学报, 2025, 60(8): 2615-2625. DOI: 10.16438/j.0513-4870.2025-0703
GONG Bo-kai, XIAO Lan, DENG Gong-nan, ZHANG Zhong-quan, JIA Wen-feng, TONG Fan, GAO Hui-le. The preparation and evaluation of dual-tumor microenvironment-responsive transformable nanoscale drug delivery system for breast cancer combination therapyJ. Acta Pharmaceutica Sinica, 2025, 60(8): 2615-2625. DOI: 10.16438/j.0513-4870.2025-0703
Citation: GONG Bo-kai, XIAO Lan, DENG Gong-nan, ZHANG Zhong-quan, JIA Wen-feng, TONG Fan, GAO Hui-le. The preparation and evaluation of dual-tumor microenvironment-responsive transformable nanoscale drug delivery system for breast cancer combination therapyJ. Acta Pharmaceutica Sinica, 2025, 60(8): 2615-2625. DOI: 10.16438/j.0513-4870.2025-0703

肿瘤微环境双响应可变形纳米粒的制备及其用于乳腺癌治疗的研究

The preparation and evaluation of dual-tumor microenvironment-responsive transformable nanoscale drug delivery system for breast cancer combination therapy

  • 摘要: 单一的纳米疗法在乳腺癌治疗中往往受纳米递送效率、肿瘤微环境(tumour microenvironment, TME) 等因素制约, 导致患者未能展现出令人满意的生存质量与生存期。为增加纳米药物在乳腺癌组织内的蓄积量, 本文设计了一种可在肿瘤微环境中响应变形的纳米粒, 并基于此开发了一种光动力疗法-免疫疗法-化疗联合治疗策略。该体系由两条长短不一的两亲性多嵌段分子链组成球状结构, 内部疏水空腔用于包载化疗药物紫杉醇(paclitaxel, PTX)。纳米粒在肿瘤微环境中受基质金属蛋白酶-2 (matrix metallopeptidase 2, MMP-2) 与活性氧(reactive oxygen species, ROS) 作用发生形态转化, 增加光敏药物焦脱镁叶绿酸a (pyropheophorbide a, Ppa) 在肿瘤内部的滞留性, 同时释放PTX与程序性细胞死亡-配体1 (programmed cell death ligand 1, PD-L1) 抑制剂dPPA。在近红外光照射下, Ppa产生ROS, 直接杀伤肿瘤细胞, 激活体内免疫响应, 同时促进纳米粒的ROS响应。本课题合成并表征了PTX@DTPD-PPP, 通过摄取实验、光响应ROS、细胞毒性实验和细胞迁移侵袭实验等, 评价双响应制剂的药物递送能力与治疗效果。研究结果表明, PTX@DTPD-PPP粒径均一稳定且表面带负电荷(水合粒径= 144 ± 1.3 nm, zeta电位= -6.8 ± 0.9 mV), 在体外TME模拟环境下可在4 h以内实现响应变形。在肿瘤细胞蓄积量与细胞毒性相较于游离光敏药物Ppa和化疗药物PTX以及其他制剂组都明显增加, 为后续动物研究打下了坚实的基础。

     

    Abstract: Ranked second and fourth respectively in incidence rate and mortality rate among various cancers, breast cancer is characterized by strong invasion, high recurrence, poor prognosis and a lack of effective treatment, rendering the quality of life and the survival time of patients unsatisfactory. Herein, we designed a dual-response shape-transformable nanomicelle consisted of two amphipathy chains of different length, within which the chemotherapeutic agent paclitaxel (PTX) is encapsulated in the hydrophobic cavity. Based on it a combined therapy of photodynamic therapy, immunotherapy and chemotherapy was developed to augment the accumulation of therapeutic drugs in breast cancer tissues and treating efficacy. Entered in tumour microenvironment (TME), the shape transformation of micelles would be triggered by reactive oxygen species (ROS) and matrix metalloproteinase-2 (MMP-2), so as to increase the retention of the photosensitizer pyropheophorbide-a (Ppa) in tumours and release PTX and D-type programmed cell death ligand 1 (PD-L1) peptide antagonist (dPPA) concurrently, thus addressing the incompatibility of long blood circulation time, tumor penetration and retention. Under the irradiation of near infrared light, ROS produced by Ppa brought about stronger killing of cancer cells, activation of host immunity and promotion of ROS response. The dual-responsive group PTX@DTPD-PPP, along with two single-responsive groups PTX@DTPD-PRP and PTX@DPD-PPP and non-responsive group PTX@DPD-PRP were initially synthesized and characterized. Through cellular uptake experiment, light-responsive ROS generation experiment, cytotoxicity test, migration and invasion test and so forth, we proved the enhancement in both drug delivery and treating effect of dual-responsive formation. These findings demonstrate that PTX@DTPD-PPP is fulfilled with an uniform particle size (144 ± 1.3 nm) and a negative surface (-6.8 ± 0.9 mV), as well as the transformation responsiveness in 4 h within in vitro experiments. Both the drug accumulation and cellular toxicity of dual-responsive group are prominently increased in contrast with free Ppa, free PTX as well as other formations, laying a foundation for the sequent in-vivo studies.

     

/

返回文章
返回